U.S. COMPANY FILING
GILEAD SCIENCES, INC. — Form 10-Q filed 2025-11-07
Filing text preview
Gilead's Q3 2025 revenue rose 3% to $7.77B, with net income surging to $3.05B from $1.25B a year ago, partly due to prior-year impairments. Nine-month net income turned positive at $6.33B. The company expects a $450M tax benefit in Q4 from a settlement. It recorded a $190M impairment on bulevirtide and faces ongoing litigation.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record